Stevanato Group Investor Presentation
Stevanato Group - 70 years of Operational Excellence
Leading Provider of Mission-Critical Solutions for the Biopharma Industry
Track Record of Growth
Global Partner of Choice
~5,600
~700
Top 25
€ 1,085M
+ 10%
employees
globally
customers in 2023
pharma
companies²
FY23 Revenue
yoy Revenue Growth
Market Leader³
#1
#1
#2
26.9%
FY23 adj. EBITDA margin¹,
~ € 945M
YE23 Backlog
Ready-to-Use Vials Pen Cartridges Pre-Filled Syringes
+670bps vs 2019
SG, Stevanato Group
¹Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA and adjusted EBITDA margin, Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 37 to 46 for a
reconciliation of non-GAAP measures.
2 As measured by 2022 revenue, according to data collected by Pharmacircle and public companies' information
3 Estimated market position in 2022, based on available market data and internal estimates and assumptions of peer CAGR increasing at or below the market rate.
Stevanato Group Investor Presentation, March 2024
4View entire presentation